Chronic Kidney Disease News

Researchers successfully used data from electronic health records to determine risk factors for kidney function decline in children with chronic kidney disease, according to a published study.

The Kidney Failure Risk Equation showed poor calibration when predicting end-stage kidney disease in children with chronic kidney disease, according to data published in the American Journal of Kidney Diseases.

In the past 30 years, kidney failure incidence has decreased to an average of 9.1 cases per million age-related population, according to data published in the Clinical Journal of the American Society of Nephrology.

The U.S. Preventive Services Task Force released a drafted research plan for routine chronic kidney disease screening that will be online and open to public comments until Feb. 15, according to a press release.

According to interview responses published in Kidney Medicine, patients with kidney failure who have experienced several forms of treatment shared three common themes when defining health.

Compared with general nephrology care, more vulnerable patients, such as older adults with advanced chronic kidney disease, may benefit more from multidisciplinary cares, according to data published in Kidney Medicine.

Among Medicare beneficiaries with end-stage kidney disease, a longer interval between last dialysis session and a surgical procedure significantly correlates with an increased risk of 90-day postoperative mortality, results showed.

Disparities by sex, race and between individual U.S. Veterans Affairs facilities exist in SGLT2i prescriptions for veterans with chronic kidney disease, type 2 diabetes mellitus and atherosclerotic cardiovascular disease, researchers found.

Among patients with diabetic kidney disease, intrarenal podocalyxin level was an independent predictor of dialysis-free survival, according to data published in Kidney Medicine.

Black and older patients with chronic kidney disease and insured by Medicare are less likely to start SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists than second-generation sulfonylureas, according to data in Kidney Medicine.